Data / Drug companies / Bamboo US Bidco LCC
Bamboo US Bidco LCC: 33 products in the FDA NDC directory, labeler code 83703
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Bamboo US Bidco LCC (labeler code 83703) lists 33 products in the FDA National Drug Code Directory, covering 4 finished drugs by generic name. By type: 24 drugs for further processing, 5 vaccines. Its main marketing category is drugs for further processing. The newest product started marketing on October 8, 2026.
The request: Watch Bamboo US Bidco LCC (FDA labeler code 83703): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 83703
- Products in commercial distribution
- 33
- Packages
- 34
- Finished drugs by generic name
- 4
- Prescription products
- 4
- Over the counter products
- 0
- Flagged as original packager
- 4 of 4 products that carry the flag
- Started marketing in the last 12 months
- 5
- Earliest marketing start
- October 20, 1976
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 24 | 72.7% |
| Biologics (BLA) | 5 | 15.2% |
| Generic drugs (ANDA) | 3 | 9.1% |
| New drug applications (NDA) | 1 | 3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 24 | 72.7% |
| Vaccines | 5 | 15.2% |
| Prescription drugs | 4 | 12.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Cyclophosphamide | 3 | 22 |
| Hepatitis b vaccine (recombinant) | 2 | 4 |
| Hepatitis b vaccine (recombinant) adjuvanted | 1 | 3 |
| Mesna | 1 | 9 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 8 | 24.2% |
| Injection, powder, lyophilized, for solution | 8 | 24.2% |
| Injection, powder, for solution | 5 | 15.2% |
| Injection, suspension | 4 | 12.1% |
| Injection | 4 | 12.1% |
| Injection, solution, concentrate | 2 | 6.1% |
| Injection, powder, lyophilized, for suspension | 1 | 3% |
| Powder, for solution | 1 | 3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Inactivated Hepatitis B Virus Vaccine | 3 |
| Cytoprotective Agent | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Temolozomide | 83703-608 | Injection, powder, lyophilized, for solution | Drugs for further processing | October 8, 2026 |
| Flucelvax | 83703-088 | Injection, suspension | Biologics (BLA) | August 1, 2026 |
| Fluzone trivalent northern hemisphere | 83703-087 | Injection, suspension | Biologics (BLA) | July 1, 2026 |
| Recombivax hb | 83703-086 | Injection, suspension | Biologics (BLA) | February 26, 2026 |
| Recombivax hb | 83703-085 | Injection, suspension | Biologics (BLA) | February 26, 2026 |
| Zolbetuximab | 83703-511 | Injection | Drugs for further processing | February 21, 2025 |
| Datopotamab deruxtecan | 83703-530 | Injection | Drugs for further processing | April 12, 2024 |
| Zolbetuximab | 83703-516 | Injection | Drugs for further processing | February 29, 2024 |
| Mecasermin | 83703-569 | Injection, solution | Drugs for further processing | January 31, 2022 |
| Mecasermin | 83703-568 | Injection, solution | Drugs for further processing | January 31, 2022 |
| Tisotumab vedotin | 83703-579 | Injection, powder, for solution | Drugs for further processing | September 20, 2021 |
| Tisotumab vedotin | 83703-578 | Injection, powder, for solution | Drugs for further processing | September 20, 2021 |
| Rituximab-arrx | 83703-576 | Injection, solution | Drugs for further processing | December 19, 2020 |
| Rituximab-arrx | 83703-575 | Injection, solution | Drugs for further processing | December 19, 2020 |
| Rituximab-arrx | 83703-574 | Injection, solution | Drugs for further processing | December 19, 2020 |
| Rituximab-arrx | 83703-573 | Injection, solution | Drugs for further processing | December 19, 2020 |
| Rituximab-abbs | 83703-582 | Injection, solution, concentrate | Drugs for further processing | December 1, 2020 |
| Rituximab-abbs | 83703-581 | Injection, solution, concentrate | Drugs for further processing | October 1, 2020 |
| Lurbinectedin | 83703-583 | Injection, powder, lyophilized, for solution | Drugs for further processing | June 15, 2020 |
| Enfortumab vedotin | 83703-571 | Injection, powder, lyophilized, for solution | Drugs for further processing | December 18, 2019 |
| Enfortumab vedotin | 83703-570 | Injection, powder, lyophilized, for solution | Drugs for further processing | December 18, 2019 |
| Trastuzumab deruxtecan | 83703-580 | Injection, powder, lyophilized, for solution | Drugs for further processing | May 22, 2019 |
| Heplisav-b | 83703-048 | Injection, solution | Biologics (BLA) | January 1, 2018 |
| Brentuximab vedotin | 83703-564 | Powder, for solution | Drugs for further processing | August 25, 2011 |
| Temozolomide | 83703-577 | Injection, powder, lyophilized, for solution | Drugs for further processing | February 27, 2009 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.